Filing Analysis
Regulation FD Disclosure
Filed May 07, 2026
LOW
Caribou Biosciences announced its financial results for the first quarter ended March 31, 2026, and provided a general business update. The disclosure was made via a press release furnished as an exhibit to the filing.
Key Facts
- Announced financial results for the quarter ended March 31, 2026
- Provided a business update in the accompanying press release (Exhibit 99.1)
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- The filing was signed by President and CEO Rachel E. Haurwitz, Ph.D.
Other SEC Filing
Filed Mar 31, 2026
MEDIUM
Caribou Biosciences announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The candidate is currently being evaluated in the ongoing CaMMouflage Phase 1 clinical trial.
Key Facts
- FDA granted RMAT designation for CB-011 on March 31, 2026.
- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy product candidate.
- The designation is for the treatment of relapsed or refractory multiple myeloma (r/r MM).
- CB-011 is currently in the CaMMouflage Phase 1 clinical trial.
Regulation FD Disclosure
Filed Mar 05, 2026
LOW
Caribou Biosciences announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release providing a business update alongside the financial data.
Key Facts
- Reported financial results for Q4 2025 and the full year ended December 31, 2025
- Filing date of March 5, 2026
- The information was furnished under Item 2.02 and is not deemed 'filed' for liability purposes
- Includes Exhibit 99.1: Press Release Issued by Caribou Biosciences, Inc. on March 5, 2026
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.